Novel Small-Molecule Antivirals for Epidemic-Potential Pathogens
Funds small-molecule antivirals that expand preparedness and treatment options for future viral epidemics and pandemics.
Emerging and re-emerging viral infections threaten European and global health, and climate change is accelerating emergence. This Research and Innovation Action strengthens the EU medical-countermeasures ecosystem by advancing small-molecule prophylactic and therapeutic candidates against a single specified virus or virus group.
Projects should select and state one permitted target group, then di…
Develop novel or existing small-molecule antiviral candidates against exactly one permitted virus or virus group: Junin/Lassa; tick-borne encephalitis/Japanese encephalitis; Andes/Hantaan/Sin Nombre; Hendra; Enterovirus D68; or Venezuelan equine encephalitis. Cover discovery, optimisation, antiviral activity and resistance, animal or organoid models, GMP batches and first-in-human safety where appropriate. Antibodies and antibody-derived proteins are excluded.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up